TY - JOUR KW - Science & Technology KW - Life Sciences & Biomedicine KW - Rheumatology KW - Lupus Erythematosus KW - Systemic KW - Rituximab KW - Immune System Diseases KW - INFLUENZA VACCINATION KW - RHEUMATOID-ARTHRITIS KW - HERPES-ZOSTER KW - PNEUMOCOCCAL VACCINATION KW - POLYSACCHARIDE VACCINE KW - ANTIBODY-RESPONSES KW - IMMUNOGENICITY KW - SAFETY KW - IMMUNIZATION KW - AUTOIMMUNE ID - discovery10188451 N2 - In recent years, treat-to-target strategy and early intervention strategies with immunosuppressive agents have attempted to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases. However, infectious complications due to side effects of medication remain a major concern in routine practice. In this regard, vaccine immunity and vaccination programmes are of the utmost importance in patients with systemic lupus erythematosus (SLE) in terms of morbidity and mortality. Encouragingly, research investigations have increased exponentially, both in monitoring the vaccines efficacy, and in determining the immune response while patients are on immunosuppression., However, in this biological era in rheumatology, relatively little data have been published investigating these parameters in those receiving biological agents, therefore, no definitive consensus about a vaccination policy for patients with SLE is currently available. In this review, we aim to address what is established about vaccinating patients with SLE on biological agents and discuss potential problems. PB - BMJ PUBLISHING GROUP TI - Approach to vaccination in systemic lupus erythematosus on biological treatment EP - 1129 AV - public Y1 - 2023/06/19/ JF - Annals of the Rheumatic Diseases A1 - Yildirim, Resit A1 - Oliveira, Tatiana A1 - Isenberg, David Alan UR - http://dx.doi.org/10.1136/ard-2023-224071 N1 - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions IS - 9 VL - 82 SP - 1123 ER -